Chemistry:Ralaniten acetate

From HandWiki
Short description: Chemical compound
Ralaniten acetate
Ralaniten acetate.svg
Clinical data
Other namesEPI-506
Routes of
administration
By mouth
Drug classNonsteroidal antiandrogen
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC27H33ClO8
Molar mass521.00 g·mol−1

Ralaniten acetate (developmental code name EPI-506) is a first-in-class antiandrogen that targets the N-terminal domain (NTD) of the androgen receptor (AR) developed by ESSA Pharmaceuticals and was under investigation for the treatment of prostate cancer.[1][2] This mechanism of action is believed to allow the drug to block signaling from the AR and its splice variants.[3][4] EPI-506 is a derivative of bisphenol A[5] and a prodrug of ralaniten (EPI-002), one of the four stereoisomers of EPI-001, and was developed as a successor of EPI-001.[6] The drug reached phase I/II prior to the discontinuation of its development.[1] It showed signs of efficacy in the form of prostatic specific antigen (PSA) decreases (4–29%) predominantly at higher doses (≥1,280 mg) in some patients but also caused side effects and was discontinued by its developer in favor of next-generation AR NTD inhibitors with improved potency and tolerability.[7]

See also

References

  1. 1.0 1.1 "Ralaniten acetate - ESSA Pharma". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800043741. 
  2. "Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer". Pharmaceutical Patent Analyst 4 (5): 387–402. 2015. doi:10.4155/ppa.15.20. PMID 26389532. 
  3. "A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.". Journal of Clinical Oncology. ISSN 0732-183X. http://meetinglibrary.asco.org/content/146857-156. Retrieved 2016-02-27. 
  4. "Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer". Current Urology Reports 17 (4): 29. April 2016. doi:10.1007/s11934-016-0584-4. PMID 26902623. 
  5. "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology 18 (5): 687–94. 2016. doi:10.4103/1008-682X.181081. PMID 27212126. 
  6. "An androgen receptor N-terminal domain antagonist for treating prostate cancer". The Journal of Clinical Investigation 123 (7): 2948–60. July 2013. doi:10.1172/JCI66398. PMID 23722902. 
  7. "ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates Clinical and Strategic Plans" (Press release). ESSA Pharma.

External links

{{Navbox

| name = Androgens and antiandrogens
| title = Androgens and antiandrogens
| state = collapsed
| listclass = hlist
| groupstyle = text-align:center;
| group1 = Androgens
(incl. AAS)

| list1 =

  | group3 = Antigonadotropins
  | list3 =
  | group4 = Others
  | list4 =
}}
| liststyle = background:#DDDDFF;
| list3 =
See also
Androgen receptor modulators
Estrogens and antiestrogens
Progestogens and antiprogestogens
List of androgens/anabolic steroids

}}